Adalimumab Significantly Reduces the Recurrence Rate of 107 Anterior Uveitis in Patients with Ankylosing Spondylitis

Total Page:16

File Type:pdf, Size:1020Kb

Adalimumab Significantly Reduces the Recurrence Rate of 107 Anterior Uveitis in Patients with Ankylosing Spondylitis VU Research Portal The evolving treatment of ankylosing spondylitis van Denderen, J.C. 2015 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) van Denderen, J. C. (2015). The evolving treatment of ankylosing spondylitis. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 10. Oct. 2021 THE EVOLVING TREATMENT OF ANKYLOSING SPONDYLITIS VRIJE UNIVERSITEIT THE EVOLVING TREATMENT OF ANKYLOSING SPONDYLITIS ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. F.A. van der Duyn Schouten, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de Faculteit der Geneeskunde op woensdag 6 mei 2015 om 11.45 uur in de aula van de universiteit, De Boelelaan 1105 ISBN: 978-94-6259-628-3 Copyright © 2015 JC van Denderen Cover: Ellen van Diek Layout: Persoonlijkproefschrift.nl, Matthijs Ariëns Printing: Ispkamp Drukkers, Enschede door Printing of thesis was financially supported by: Pfizer BV, Janssen-Cilag BV, AbbVie Johannes Christiaan van Denderen BV, Mundipharma BV, UCB Pharma BV, Will-Pharma BV. geboren te Kampen All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without permission of the author. promotor: prof.dr. J.W.J. Bijlsma CONTENTS copromotoren: dr. I.E. van der Horst-Bruinsma dr. M.T. Nurmohamed Chapter 1 Introduction: 1. General introduction. 8 2. History of the disease ankylosing spondylitis. 11 3. History of therapy in ankylosing spondylitis. 21 4. Objectives and outline of this thesis. 29 Chapter 2 Efficacy and safety of mesalazine (Salofalk®) in an open study 41 of 20 patients with ankylosing spondylitis. Chapter 3 Statin therapy might be beneficial for treating patients with 51 ankylosing spondylitis. Chapter 4 Double blind, randomised, placebo controlled study of 57 leflunomide in the treatment of active ankylosing spondylitis. Chapter 5 Decreased clinical response to infliximab in ankylosing 71 spondylitis is correlated with anti-infliximab formation. Chapter 6 Elevated liver enzymes in patients with ankylosing 81 spondylitis treated with etanercept. Chapter 7 What do we miss? ASAS non-responders on anti-TNF 95 therapy show improvement in performance-based physical function. Chapter 8 Adalimumab significantly reduces the recurrence rate of 107 anterior uveitis in patients with ankylosing spondylitis. Chapter 9 Etanercept increases bone mineral density in ankylosing 121 spondylitis, but does not prevent the increase of vertebral fractures. Chapter 10 1. General discussion and summary. 138 2. Nederlandse samenvatting. 162 3. Dankwoord. 168 4. Curriculum vitae. 169 5. List of publications. 170 6. List of abbreviations and illustrations. 173 CHAPTER 1 Introduction 1. General introduction. 2. History of the disease ankylosing spondylitis. 3. History of therapy in ankylosing spondylitis. 4. Objectives and outline of this thesis. Chapter 1 Introduction 1 GENERAL INTRODUCTION. limitation of mobility of the spine and thorax. After many years flattening of the lumbar lordosis and increase of the thoracic kyphosis can occur; which produce The subject of this thesis is the disease ankylosing spondylitis (AS) and particularly the characteristic curved and immobile posture. In addition, this posture becomes various aspects of drug therapy in AS. aggravated by flexion contractures in the hips in case of hip arthritis. Some AS AS is the prototype of a group of diseases, called spondyloarthritides, which have patients can not stand erect, nor see well straight forward (figure 1). The severity of 1 inflammation of the spine and sacroiliac joints as common features. Other diseases AS can range from mild disease and limited radiological changes to a severe disease belonging to spondyloarthritis (SpA) are psoriatic arthritis, reactive arthritis, arthritis with persisting disease activity and disability. Pain and structural damage can associated with inflammatory bowel disease and a subgroup of juvenile idiopathic cause limitation of mobility, functional impairment, reduction in well being and can arthritis. In the Netherlands AS is often called “ziekte van Bechterew”. lead to absence and disability at work [8]. Predictors of functional impairment are: 2 AS is characterised by a chronic sterile inflammation of joints and entheses worse initial features of the disease, older age, smoking, uveitis and peripheral joint (entheses are the sites of attachment of tendons, ligaments and joint capsules). disease, especially hip involvement [6, 9-12]. The inflammation in AS is localised primarily in the sacroiliac joints and spine, Patients with AS have an increased risk of mortality [10]. In a review the standardized 3 but peripheral joints can be involved as well. The peripheral arthritis is usually an mortality ratio was approximately 1.7 (range 1.5-1.9), which for the most part could asymmetric oligoarthritis of the lower extremities, including the hips. In contrast to be ascribed to cardiovascular diseases [13]. rheumatoid arthritis the inflammation does in a lesser degree lead to destruction (erosions) of bone, but can lead to local ossification. This hyperostosis can lead In AS extra-spinal and extra-articular manifestations are observed. AS is associated 4 to ankylosis and in some cases to the characteristic bamboo spine. This has given with skin disease (psoriasis), inflammatory bowel disease (ulcerative colitis and the disease its name: the Greek ankylos means stiff/curved and spondylos means Crohn’s disease) and preceding enteral or genitor-urinal infections (reactive vertebra/spine. arthritis). One third of the patients with AS experience attacks of inflammation of the eye (acute anterior uveitis) [14]. Problems of the heart (conduction disturbance 5 In mid-Europe AS affects 0.3-0.5 % of the population and the prevalence for SpA is and aortic root anomaly) and sometimes apical pulmonary fibrosis do occur. 1-2% [1]. The Human Leukocyte Antigen (HLA) B27 is the most important genetic The incidence of osteoporosis and vertebral fractures is increased, as well as the factor linked to the disease. In more than 90% of Caucasian AS patients HLA-B27 is incidence of cardiovascular disease [15-18]. 6 present. This explains the familial aggregation of AS and the higher prevalence of AS in the northern countries, where HLA-B27 is more prevalent [2]. Men are affected In the next paragraph, the historical context of the disease AS will be discussed, more often than women (ratio 2-3 to 1) [1, 3]. including the evolution towards the recognition as a separate disease. In the third The pathophysiology of the disease is not fully clarified. Probably, in subjects with paragraph of the introduction the therapy of AS in the past and present will be 7 genetic susceptibility, auto-inflammatory processes are triggered by environmental discussed. At the end of the introduction an outline of this thesis is given. factors (for example enteral or urogenital microbes and smoking), mechanical stress and/or HLA-B27 binding peptides [4-6]. 8 Laboratory investigation can show raised acute phase reactants (erythrocyte sedimentation rate (ESR) and C-reactive protein), but often does not [7]. Diagnostic for AS are radiological changes of the sacroiliac joints: sclerosis, erosions and ankylosis. Later in the disease process similar changes can be seen in the rest of the 9 spine at the corners of the spinal corpora, in the intervertebral and costovertebral joints. 10 In most cases the disease starts in young adults (<30 years), but is diagnosed several years later. General symptoms, like anaemia and tiredness, often occur. The inflammation causes pain and stiffness in the buttocks, the lower back and other parts of the spine. The complaints are worst in the late night and early morning and improve with moving and not with rest. Inflammation and ankylosis can cause 8 9 Chapter 1 Introduction 2 HISTORY OF THE DISEASE ANKYLOSING SPONDYLITIS. The evolution of ankylosing spondylitis (AS) towards a separate disease entity is described in this paragraph, based on old descriptions, pathophysiological findings in animal and human skeletons and new scientific developments like the 1 invention of X-rays and DNA-sequencing, that unravelled the HLA-B27 association. Classification criteria for AS were developed and later AS was embedded in the broader spectrum of axial spondyloarthritis (SpA). 2 Old literature and art Luke, one of the four evangelists, was a Greek physician who wrote around Anno Domini 75 in verse 13 of the Gospel ascribed to him: “Ende siet / daer was eene 3 vrouwe / die hadde eenen geest der kranckheyt achtien jaren / ende sy was krom / ende en konde niet wel op-sien” [19]. Caelius Aurelianus, a Roman physician in the fifth century, described a patient in Figure 1. Progression of ankylosing spondylitis in a patient with severe disease. By 1957, 10 “De Ischiadicis et Psoadicis”: The patient is seized by pain in the nates, moves years after the onset of disease, he has very limited extension of his spine as evidenced by the 4 loss of lordosis and exaggeration of thoracic kyphosis (spine is fusing in flexion). By 1967, he slowly, and can only bend or stand erect with difficulty [20].
Recommended publications
  • Juden in Erlangen
    Juden in Erlangen Band I K - P Familienbuch der jüdischen Familien aus Erlangen, Bruck und Büchenbach ✡ Prof. Dr. Emmy Noether 1882-1935 Mathematikerin von Wolfgang Appell, Erlangen Selbstverlag (Update März 2021) Inhaltsverzeichnis Genealogien Kappel, Salomon * 1836, Mediasch, Dr. phil. u. Realschullehrer in Erlangen Karpf, Joseph * 1857, Bischofsheim an der Rhön, Kaufmann in Erlangen Kaswan, Mendel * ca. 1890, Sniatyn, displaced person 1947 in Erlangen Katz, Karl * 1843, Tost (Toszek), Witwe und Sohn lebten in Erlangen Katz, Simon * 1869, Tost (pol. Toszek), Fotograph in Erlangen Kirschner, Alfred * 1883, Skupach bei Weseritz, heiratet in Erlangen Klein, Joseph * 1807, Memmelsdorf, Rabbiner, Dr. phil. promoviert 1840 in Erlangen Kohler, Kaufmann * 1843, Fürth, Rabbiner, Dr. phil. promoviert 1867 in Erlangen Kohlmeier, Hermann * 1813, Eschenau, Schüler in Erlangen 1830-1831 Kohn, Josef * 1810, Markt Erlbach, Ehefrau aus Erlangen-Büchenbach Kohn, Salomon * 1855, Burgkunstadt, Ehefrau aus Erlangen-Bruck Kraus, Samuel * ca. 1860, Ehefrau aus Erlangen-Bruck Kunst, David * 1824, Baiersdorf, Schüler in Erlangen 1833-1836 Kurzmann, Salomon Samson * 1756, Erlangen-Bruck Kusel, Carl * ca. 1841, Direktor der Spinnerei und Weberei ERBA in Erlangen Lambert, Baruch * 1815, Erlangen-Bruck Lambert, Isaak Nathan Levi * 1774, Erlangen-Bruck Lambert, Nathan Isaak * 1812, Erlangen-Bruck Lambert, Samuel J. * 1834, Erlangen-Bruck Lambert, Simon * 1826, Erlangen-Bruck Lasker, Emanuel * 1868, Berlinchen (Barlinek), Dr. phil. promoviert in Erlangen, Schachweltmeister Lehmaier, Jonas (John) * 1815, Baiersdorf, Dr. med., Schüler in Erlangen Lehmaier, Abraham * 1817, Baiersdorf, Schüler in Erlangen 1827-1831 Lehmaier, Moses (Morris) * 1819, Baiersdorf, Schüler in Erlangen 1831-1836 Lehmann, Lippmann * 1822, Dr. med., Schule, Studium, Promotion in Erlangen 1835-1847 Lehmann, Sigmund (Samuel) * 1820, Schule in Erlangen 1835-1836 Levin, Joseph * 1822, Erlangen-Bruck Lewin, Marx Joseph Levi * ca.
    [Show full text]
  • People Behind Exclusive Eponyms of Radiologic Signs (Part I)
    Canadian Association of Radiologists Journal 60 (2009) 201e212 www.carjonline.org History / Histoire People Behind Exclusive Eponyms of Radiologic Signs (Part I) Zeev V. Maizlin, MDa,*, Peter L. Cooperberg, MDb, Jason J. Clement, MDb, Patrick M. Vos, MDb, Craig L. Coblentz, MDa aDepartment of Radiology, McMaster University Medical Centre, Hamilton, Ontario, Canada bDepartment of Radiology, St Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada Introduction were picked up and cited to create the eponym. The initial citation, in fact, was the birth act for the eponym. Chrono- An eponym in medicine is the name of a disease or logically, most eponyms used in radiology today were a structure based on or derived from the name of a person. created in the first half of the 20th century. No eponyms seem Eponyms are frequently used in the fields of both radiology to be originating from articles published starting from the and clinical disciplines. They play an important role in late 1970s. proper reporting and communication. Use of eponyms There is an interesting trend in the spelling of eponyms provides an efficient, easy, and short way of describing signs and noticed by F. M. Hall [1]. Traditionally, eponyms were and syndromes. Eponyms also honor those who have valu- recorded as possessives, as if the sign or disease belonged to ably contributed to medicine. Eponyms are links to our the honored individual (eg, Rigler’s). Over the past few history. Historical knowledge about eponyms opens up to us decades, a trend, started by omitting the apostrophe the personality of the people who developed the modern (Riglers), resulted more recently in elimination of the science of medicine.
    [Show full text]
  • Handbook of Nutrition and Ophthalmology (Nutrition and Health)
    HANDBOOK OF NUTRITION AND OPHTHALMOLOGY Giuseppe Arcimboldo, Vertemnus (1591), Courtesy of Skoklosters Slott, Bålsta, Stockholm. Vertemnus (or Vortumnus) was an Etruscan god who was responsible for the transformation of plants from flowering to the bearing of fruit. © Skokloster castle photo Samuel Uhrdin HANDBOOK OF NUTRITION AND OPHTHALMOLOGY By RICHARD D. SEMBA, MD, MPH The Wilmer Eye Institute, The Johns Hopkins University and Hospital, Baltimore, Maryland © 2007 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapr.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug.
    [Show full text]
  • Yeni Tıp Tarihi Araştırmaları Düzenleme : Nobel Tıp Kitabevleri Sayfa Düzeni : Nobel Tıp Kitabevleri Matbaa / Cilt : No-Bel Matbaacılık San
    YENİ TIP TARİHİ ARAŞTIRMALARI THE NEW HISTORY OF MEDICINE STUDIES Editör GÜLTEN DİNÇ 21 2015 Kapak resmi / Cover illustration Doç. Dr. İnci HOT (1970-2015) “Dergimizin bu sayısı HİLMİ BARLAS EĞİTİM VAKFI’nın katkıları ile yayımlanmıştır.” ISSN 1300 - 669X Özgün adı : Yeni Tıp Tarihi Araştırmaları Düzenleme : Nobel Tıp Kitabevleri Sayfa düzeni : Nobel Tıp Kitabevleri Matbaa / Cilt : No-bel Matbaacılık San. Tic. Ltd. Şti. Sertifika No: 12565 İstanbul, 2016 YENİ TIP TARİHİ ARAŞTIRMALARI THE NEW HISTORY OF MEDICINE STUDIES Yıl: 2015 Sayı: 21 Editör / Editor Gülten Dinç Sahibi ve Yazı İşleri Müdürü: Türk Tıp Tarihi Kurumu adına Başkan, Prof. Dr. Nuran Yıldırım Yayın Kurulu / Editorial Board: Nuran Yıldırım, Emre Dölen, Gülten Dinç, Burhan Akgün, Ayten Arıkan İngilizce Editörleri: Murat Civaner, Hakan Ertin Kısaltma: Y Tıp Tarihi Arştr Abbreviation: N History Med Stud Yazışma Adresi: Gülten Dinç İ.Ü. Cerrahpaşa Tıp Fakültesi, Tıp Tarihi ve Etik Anabilim Dalı, 34098, Fatih-İstanbul Telf.: +90 212 529 03 64, +90 212 414 30 00 “22680” e-posta: [email protected], [email protected] YENİ TIP TARİHİ ARAŞTIRMALARI The New History of Medicine Studies, 2015;21 HAKEM KURULU Referees Committee Ahmet ACIDUMAN, Ankara Ayten ALTINTAŞ, İstanbul Ayten ARIKAN, İstanbul Fatih ARTVİNLİ, İstanbul Adnan ATAÇ, Ankara Elif ATICI, Bursa Murat CİVANER, Bursa Oya DAĞLAR MACAR, İstanbul Hanzade DOĞAN, İstanbul Emre DÖLEN, İstanbul Ömür ELÇİOĞLU, Eskişehir Şahap ERKOÇ, İstanbul Nermin ERSOY, Kocaeli Hakan ERTİN, İstanbul Nilüfer GÖKÇE, Edirne Şefik GÖRKEY, İstanbul Feza GÜNERGUN, İstanbul H. Hüsrev HATEMİ, İstanbul Yeşim IŞIL ÜLMAN, İstanbul Funda Gülay KADIOĞLU, Adana Selim KADIOĞLU, Adana Aykut KAZANCIGİL, İstanbul Sait NADERİ, İstanbul Gülbin ÖZÇELİKAY, Ankara Abdullah ÖZEN, Elazığ Feryal SAYGILIGİL, İstanbul Sevgi ŞAR, Ankara Mine ŞEHİRALTI, Kocaeli İlter UZEL, Adana İsmail YAKIT, Antalya Nuran YILDIRIM, İstanbul M.
    [Show full text]